The abstract is read at the publisher; the summary is JClub's.
In Mali’s LAKANA cluster trial, twice-yearly azithromycin for 1–11-month-old infants for 2 years did not increase macrolide resistance in Streptococcus pneumoniae at 36 months.
- Why it matters: Mass azithromycin can reduce under-five mortality, but its potential to raise antimicrobial resistance is a key safety concern that needs direct trial evidence.
- What they did: LAKANA enrolled infants in 59 villages and collected 5,025 nasopharyngeal and 5,021 rectal swabs at baseline and 12-, 24-, and 36-months, testing macrolide resistance in Streptococcus pneumoniae and Escherichia coli by disk diffusion or E-tests.
- The result: At 36 months, placebo vs twice-yearly differences were 1.0% (95% CI [-4.7, 6.8]) for Streptococcus pneumoniae and 1.3% (95% CI [-2.4, 4.9]) for Escherichia coli, meeting the +10 percentage-point noninferiority margin.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.